Acrivon Therapeutics, Inc. (ACRV) Financial Statements (2026 and earlier)

Company Profile

Business Address 480 ARSENAL WAY, SUITE 100
WATERTOWN, MA 02472
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments118,582179,480127,458127,751
Cash and cash equivalent41,49939,81836,01529,519
Short-term investments77,083139,66291,44398,232
Deferred costs 500500300 
Other undisclosed current assets1,3631,6491,9344,344
Total current assets:120,445181,629129,692132,095
Noncurrent Assets
Operating lease, right-of-use asset2,5273,5544,4294,770
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization4,8894,4713,4792,092
Long-term investments and receivables  5,089 41,881
Long-term investments  5,089 41,881
Restricted cash and investments203198414388
Other noncurrent assets1,6531,647  
Other undisclosed noncurrent assets   251 
Total noncurrent assets:9,27214,9598,57349,131
TOTAL ASSETS:129,717196,588138,265181,226
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities8,3896,9119,7654,258
Accounts payable2,2777585,048904
Accrued liabilities6,1126,1534,7173,354
Other undisclosed current liabilities7,27510,3033,5382,258
Total current liabilities:15,66417,21413,3036,516
Noncurrent Liabilities
Liabilities, other than long-term debt1,5372,5883,7674,235
Operating lease, liability1,5372,5883,7674,235
Total noncurrent liabilities:1,5372,5883,7674,235
Total liabilities:17,20119,80217,07010,751
Equity
Equity, attributable to parent112,516176,786121,195170,475
Common stock31312322
Additional paid in capital387,255373,284237,675226,580
Accumulated other comprehensive income (loss)111447(83)(95)
Accumulated deficit(274,881)(196,976)(116,420)(56,032)
Total equity:112,516176,786121,195170,475
TOTAL LIABILITIES AND EQUITY:129,717196,588138,265181,226

Income Statement (P&L) ($ in thousands)

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Revenues
(Sublease Income)
   134537
Gross profit:   134537
Operating expenses(84,114)(89,199)(67,103)(32,657)
Other undisclosed operating loss   (134)(537)
Operating loss:(84,114)(89,199)(67,103)(32,657)
Nonoperating income6,2098,64313,8151,490
Investment income, nonoperating   7,000 
Other nonoperating income (expense)(270)(558)6,7151,490
Loss from continuing operations before equity method investments, income taxes:(77,905)(80,556)(53,288)(31,167)
Other undisclosed income from continuing operations before income taxes80   
Loss from continuing operations:(77,825)(80,556)(53,288)(31,167)
Other undisclosed net loss(80) (7,100) 
Net loss available to common stockholders, diluted:(77,905)(80,556)(60,388)(31,167)

Comprehensive Income ($ in thousands)

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Net loss:(77,905)(80,556)(60,388)(31,167)
Other comprehensive income    31,262
Comprehensive income (loss):(77,905)(80,556)(60,388)95
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(336)53012 
Comprehensive income (loss), net of tax, attributable to parent:(78,241)(80,026)(60,376)95

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: